Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

China Blocks GSK Generic BPH Drug Due to Safety Concerns

publication date: Nov 1, 2022

China has banned a GSK generic drug, due to worries that a sloppy manufacturing process might cause infections. Avodart (dutasteride) is a generic therapy for urinary retention associated with benign prostatic hyperplasia (BPH). China banned Avodart for 18 months, until April 29, 2024 and also banned GSK from participating in volume-based procurement agreements for the same period of time. GSK said Avodart was its only drug that qualified for the hospital procurement program, implying that the ban would not materially affect the company’s China revenues. More details....

Stock Symbol: (NYSE: GSK)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital